Filing Flows › Comparisons › LMAT vs HTFL
Lemaitre Vascular vs Heartflow: LMAT and HTFL compared
Lemaitre Vascular is the larger company: $68.0M of revenue in its latest quarter (Q3 2026) against $64.1M for Heartflow (Q2 2026). Heartflow is growing faster (+48% against +11% a year earlier). Lemaitre Vascular is more profitable, with an operating margin of 26.0% against -27.9%.
Where the money goes: LMAT and HTFL
Lemaitre Vascular (LMAT) · Q3 2026
Lemaitre Vascular, Q3 2026: revenue $68.0M (+11% year over year), operating margin 26.0%, net earnings $15.0M, operating cash flow $22.0M. The chart follows the revenue to costs, profit and cash.
Heartflow (HTFL) · Q2 2026
Heartflow, Q2 2026: revenue $64.1M (+48% year over year), operating margin -27.9%, net loss $15.7M, operating cash flow −$8.6M. The chart follows the revenue to costs, profit and cash.
| Lemaitre Vascular (LMAT) | Heartflow (HTFL) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $68.0M | $64.1M |
| Revenue growth, Y/Y | +11% | +48% |
| Gross margin | 71.7% | — |
| Operating margin | 26.0% | -27.9% |
| Net earnings | $15.0M | −$15.7M |
| Net margin | 22.1% | -24.6% |
| Operating cash flow | $22.0M | −$8.6M |
| Free cash flow | $19.7M | — |
| Market value | $2.0B | — |
| P/E | 30.2× | — |
| Analysts’ mean target | $107.00 | — |
Questions
Which is bigger, Lemaitre Vascular or Heartflow?
Lemaitre Vascular is the larger company: $68.0M of revenue in its latest quarter (Q3 2026) against $64.1M for Heartflow (Q2 2026).
Is Lemaitre Vascular or Heartflow growing faster?
Heartflow is growing faster (+48% against +11% a year earlier).
Which is more profitable, Lemaitre Vascular or Heartflow?
Lemaitre Vascular is more profitable, with an operating margin of 26.0% against -27.9%.
More: Lemaitre Vascular earnings · how Lemaitre Vascular makes money · Heartflow earnings · how Heartflow makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.